System-Specific Biopharmaceuticals

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

DRMA

DRMAW

SBIO

Analyst Anthony Vendetti from Maxim Group has reiterated a Buy rating on Dermata Therapeutics, maintaining a 12-month price target of $4. He cites the company's progress in launching its first skincare product, a disciplined cost structure, and sufficient liquidity into late 2026 as key factors. Despite early-stage risks, Vendetti believes the stock's valuation is attractive relative to its growth potential.

Tip Ranks

Dermata Therapeutics

VanEck Biotech ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4

Earnings Watch

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0

DERMA E, a dermatologist-recommended skincare brand, announces a bold rebranding with a new campaign titled "A Lil' Derm Goes a Long Way." The initiative emphasizes its dermatologist-backed heritage and aims to simplify skincare education. The campaign features playful visuals and expert insights from dermatologists, focusing on key product lines like Anti-Wrinkle and Vitamin C. Modernized packaging and messaging will enhance consumer experience, with the brand refresh launching online and in retail starting June 8, 2026.

prnewswire

Ulta Beauty

10:15 ETDERMA E Reintroduces Itself with a Bold New Direction and Fresh Campaign, "A Lil' Derm Goes a Long Way," Reinforcing Dermatologist-Backed Skincare and New Packaging

Dermapharm Holding SE has announced the upcoming publication of its quarterly financial report for Q1 of the 1st half-year. The report will be disclosed on May 13, 2026, in both German and English. The announcement was made on May 4, 2026, and the company is responsible for the content of this announcement. Further details can be found on their official website.

EQS Group AG

Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

Veradermics Announces Pricing of Upsized Public Offering and Private Placement | MANE Stock News

StockTitan

VeraDermics

Veradermics Announces Pricing of Upsized Public Offering and Private Placement | MANE Stock News

GRTX

The global keloid treatment market is evolving into a clinically driven segment, projected to grow from USD 4.29 billion in 2026 to USD 6.20 billion by 2036, at a CAGR of 3.8%. This shift emphasizes multi-modal therapies, combining laser treatments and pharmacological agents, as the new standard. With around 100 million affected individuals globally, particularly in diverse populations, the market is gaining attention from healthcare leaders and investors. Key players include Bausch Health, Sciton, and Galderma, with innovations in treatment protocols and regulatory changes shaping future growth.

MorningStar

Galera Therapeutics

Bausch Health

Health Care Select Sector SPDR

iShares US Pharma

iShares Global Healthcare

VG Health

Global Keloid Treatment Market Outlook | North America, Asia Pacific, Europe Lead | Bausch Health, Sciton, Galderma Drive Multi-Modal Dermatology Innovation

Interim data from two investigator-initiated trials (IITs) supported by Galderma highlight the effectiveness of Sculptra® and Restylane® in addressing aesthetic changes due to menopause and weight loss medications. The trials showed significant improvements in skin hydration and quality, particularly when Restylane Skinboosters were used first. The findings emphasize the need for regenerative aesthetic treatments in managing skin changes associated with menopause and medication-driven weight loss, reinforcing Galderma's commitment to supporting independent research and patient needs.

Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 8-K: FY2025 Revenue: USD 0

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 | DRMA Stock News

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025  | DRMA Stock News

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM)(DRMAW.US)

Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0

10:15 ETDERMA E Reintroduces Itself with a Bold New Direction and Fresh Campaign, "A Lil' Derm Goes a Long Way," Reinforcing Dermatologist-Backed Skincare and New Packaging

Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements